Prospective of a natural remedy, silymarin from milk thistle, for treating chronic hepatitis

doi:10.12092/j.issn.1009-2501.2019.05.015

Abstract

Abstract:

Silybum marianum is a plant of the genus salicaceae,and its flavonoid natural product silymarin has many pharmacological activities such as anti-oxidation,anti-inflammatory,anti-cancer,liver-protecting,lipid-lowering,etc.It has significant effects on liver diseases such as viral hepatitis,drug-induced hepatitis,alcoholic hepatitis,and autoimmune hepatitis.This article reviews the research progress and mechanism of classic hepatoprotectant-silymarin in the treatment of various liver diseases,in order to provide reference for the re-development and application of silymarin in the field of anti-hepatitis.

Key words: milk thistle, silybin, chronic hepatitis, liver protection, cytokines

CLC Number:

R285
R51

ZHAI Shuo，LI Na，CHEN Beining，KOU Junping，XING Weifan，ZHANG Pinghu. Prospective of a natural remedy, silymarin from milk thistle, for treating chronic hepatitis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 573-579.

References

［1］张通,郭万里,聂作明,等.水飞蓟的基源鉴定与质量分析［J］.浙江理工大学学报(自然科学版),2017,37(3):467-474.
［2］Wang H, Yan T, Xie Y,et al. Mechanism-based inhibitory and peroxisome proliferator-activated receptor alpha-dependent modulating effects of silybin on principal hepatic drug-metabolizing enzymes ［J］. Drug Metab Dispos, 2015，43(4): 444-454.
［3］Neha, Jaggi AS, Singh N. Silymarin and its role in chronic diseases［J］.Adv Exp Med Biol, 2016,929:25-44.
［4］Federico A, Dallio M, Loguercio C. Silymarin/Silybin and chronic liver disease: a marriage of many years［J］. Molecules, 2017, 22 (2): pii: E191.
［5］Li HB, Yang YR, Mo ZJ, et al. Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition［J］.Braz J Med Biol Res, 2015,48(5):440-446.
［6］Sornsuvit C, Hongwiset D, Yotsawimonwat S, et al. The bioavailability and pharmacokinetics of silymarin SMEDDS formulation study in healthy thai volunteers［J］. Evid Based Complement Alternat Med, 2018, 2018:1507834.
［7］Zarrelli A, Romanucci V, Tuccillo C, et al. New silibinin glyco-conjugates: synthesis and evaluation of antioxidant properties ［J］. Bioorg Med Chem Lett, 2014, 24(22):5147-5149.
［8］向英歌. 张武主任治疗慢性肝炎学术经验总结及临床研究［D］.中国中医科学院,2016.
［9］邢杰,陈英利,陶淑华,等.免疫性肝损伤相关细胞因子研究进展［J］.中国病原生物学杂志,2009,4(1):71-72,75.
［10］Cruz HM, Barbosa JR, Baima Colares JK, et al. Cross-sectional study to determine viral hepatitis knowledge in different urban populations in Brazil［J］. World J Hepatol, 2018, 10(11):867-876.
［11］Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection ［J］. World J Gastroenterol, 2012, 18(20): 2443-2451.
［12］Kayaaslan B, Akinci E, Ari A, et al. A long-term multicenter study: entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients［J］. Clin Res Hepatol Gastroenterol, 2018,42(1):40-47.
［13］Umetsu T, Inoue J, Kogure T, et al. Inhibitory effect of silibinin on hepatitis B virus entry［J］. Biochem Biophys Rep, 2018,14:20-25.
［14］曾传莉,胡爱荣,胡耀仁,等.恩替卡韦联合微生态制剂治疗乙肝肝硬化患者的临床疗效研究［J］.中国临床药理学与治疗学,2018,23(7):796-801.
［15］卓燊,陈君,秦海洸.水飞蓟宾磷脂复合物联合阿德福韦酯对56例慢性乙肝患者疗效观察［J］. 中国药物经济学, 2014,9(1): 229-230.
［16］张友琴.拉米夫定联合水飞蓟宾葡甲胺片治疗慢性乙型肝炎的疗效观察［J］.临床医药文献电子杂志,2016,3(7):1335,1338.
［17］Lovelace ES, Wagoner J, MacDonald J, et al. Silymarin suppresses cellular inflammation by inducing reparative stress signaling ［J］. J Nat Prod, 2015,78(8):1990-2000.
［18］Vecchione G, Grasselli E, Voci A, et al. Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells ［J］. World J Gastroenterol, 2016, 22(26): 6016-6026.
［19］Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy ［J］. Gastroenterology, 2008, 135(5): 1561-1567.
［20］DebRoy S, Hiraga N, Imamura M, et al. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy［J］. J Viral Hepat, 2016, 23(9):708-717.
［21］Blaising J, Lévy PL, Gondeau C, et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking［J］. Cell Microbiol, 2013, 15(11):1866-1882.
［22］Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase ［J］. Gastroenterol, 2010, 138(3): 1112-1122.
［23］袁玲,杨永耿,沈有秀,等.药物性肝损伤的研究进展［J］.临床肝胆病杂志,2017,33(2):375-378.
［24］姬粉芝,刘俊巧.水飞蓟宾胶囊治疗抗结核药物性肝炎的疗效探讨［J］.中国继续医学教育,2016,8(34):184-186.
［25］张红.水飞蓟宾治疗抗精神病药物引起的肝功能损害的疗效观察［J］.新疆医学,2014,44(10):27-28.
［26］Papackova Z, Heczkova M, Dankova H, et al. Silymarin prevents acetaminophen-inducedhepatotoxicity in mice［J］. PLoS ONE,2018,13(1):e0191353.
［27］Ramakrishnan G, Lo Muzio L, Elinos-Baez CM, et al. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells［J］. Cell Prolif,2009,42(2):229-240.
［28］Xiang X, You XM, Zhong JH, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection ［J］. J Hepatol, 2017, 67(4):885-886.
［29］Kim JS, Han NK, Kim SH, et al. Silibinin attenuates radiation-induced intestinal fibrosis and reverses epithelial-to-mesenchymal transition［J］. Oncotarget, 2017, 8(41):69386-69397.
［30］Stickel F, Datz C, Hampe J, et al. Pathophysiology and management of alcoholic liver disease: update 2016［J］. Gut Liver, 2017, 11(2):173-188.
［31］Zeng T, Zhang CL, Xiao M, et al. Critical roles of kupffer cells in the pathogenesis of alcoholic liver disease: from basic science to clinical trials［J］. Front Immunol, 2016, 7:538.
［32］姚祥,蒋静.酒精肝的临床症状及水飞蓟宾对酒精肝的治疗分析［J］.当代医学,2017,23(13):62-63.
［33］Federico A, Dallio M, DI Fabio G, et al. Silybin-phosphatidylcholine complex protects human gastric and liver cells from oxidative stress［J］. In Vivo, 2015, 29(5):569-575.
［34］Das SK, Mukherjee S. Biochemical and immunological basis of silymarin effect, a milk thistle (Silybum marianum) against ethanol-induced oxidative damage［J］.Toxicol Mech Methods, 2012,22(5):409-413.
［35］Kapila N, Higa JT, Longhi MS, et al. Autoimmune hepatitis:clinical review with insights into the purinergic mechanism of disease［J］. J Clin Transl Hepatol, 2013, 1(2):79-86.
［36］Ma WT, Chang C, Gershwin ME, et al. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review ［J］. Autoimmun, 2017, 83: 95-112.
［37］黄巧玲.自身免疫性肝炎的诊断及治疗研究进展［J］.内科,2017,12(1):43-45,62.
［38］张永州,吴先闯,刘瑜新,等.水飞蓟素对伴刀豆球蛋白A致免疫性肝损伤小鼠的保护作用［J］.中国新药与临床杂志,2017,36(7):417-420.
［39］黄彩玲,肖柳英,潘竞锵.水飞蓟素对小鼠肝损伤保护作用及机理研究［J］.中国民族民间医药,2012,21(15):36-38.
［40］Abenavoli L,Milic N.Silymarin for liver disease［J］. Liv Pathophysiol,2017,621-631.DOI:10.1016/B978-0-12-804274-8.00045-X.
［41］王川雨,林尤直.阿德福韦酯联合水飞蓟宾治疗慢性乙型肝炎合并脂肪肝疗效探讨［J］.中国实用医药,2018,13(23):95-97.

[1]	CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei. Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248.
[2]	MA Yitong, MA Jianhong, GAO Yating, LIU Chang. Pathogenic mechanism and research progress of adipocytokines in endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1315-1320.
[3]	GAO Jiarong, SHI Miaomiao, CHEN Hao, JIANG Hui, QIN Xiujuan. Effect of Qiteng Xiaozhuo granule mediating miR-339-5p on inflammatory indexes in rats with chronic glomerulonephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 457-465.
[4]	HE Xiujuan, MA Huike, LIU Qingwu, CHEN Jia, LIN Yan, LI Ping. Research progress of cytokines in wound healing [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 579-585.
[5]	LI Min, WANG Shanshan, LIU Zhonghe, JIANG Deguo. Expression and mechanism of p38MAPK signaling pathway in chronic pulpitis rats with pain [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 644-649.
[6]	BU Zhangyu, WU Liming, YU Xiaohong, LIU Jue, DENG Lin. Investigation of curative effect and mechanism of Chaihu Jiedu Decoction on condyloma acuminatum [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 681-686.
[7]	HUANG Lijia, HUANG Yang, KONG Jinsong, ZHENG Xin, GONG Xiaokang, RUAN Jianwei, WANG Haibao. Inhibition of articular cartilage degeneration by atorvastatin calcium via STAT1-caspase-3 signaling axis in rats with knee osteoarthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 743-748.
[8]	ZHOU Yong, YING Li, XU Jiajia, DING Shixiong, HU Airong, GAO Guosheng. Effects of soluble human leukocyte antigen G on the standardized treatment of hepatitis C patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 809-813.
[9]	YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun. Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
[10]	LI Fang, ZHENG Liupu, WENG Jianlong, GUO Tao, SONG Xingwei, ZHENG Rongyuan. Therapeutic time window of effectiveness for idazoxan ameliorating brain damage of rats with experimental autoimmune encephalomyelitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 1-7.
[11]	CHEN Yonghua, CAO Qunfen, HONG Qiongyi, WANG Shumin. Effect of tenofovir disoproxil fumarate on serum FGF-23，β2-MG，Cys-C and RBP level in patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 799-804.
[12]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[13]	MAO Hongxia, JIN Lingqing, LIU Shuangchun. Effect of glucosamine sulfate combined with Shenmai injection on knee osteoarthritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 560-564.
[14]	ZHANG Peihong, CHEN Xiaohong, CHEN Bingrong, LI Huajun. Study on asthmatic children serum cytokine levels and saccharomyces boulardii intervention [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 332-336.
[15]	SHI Liu-xia, JIN Yue-long, WANG Xiang-yu, HE Lian-ping, YAO Ying-shui. The expression of high sensitive C-reactive protein and inflammation cytokines in periodontitis patients with hypertension and type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 541-545.